Spero reports Q3 2026 results, plans SP001 Phase 2 in IgG4-RD for Q2 2027
Spero said cash of $107.9 million should fund operations into the second half of 2029 as it advances its in-licensed CD40L antibody toward a mid-2027 Phase 2 start.
SEC filing
9 stories
Spero said cash of $107.9 million should fund operations into the second half of 2029 as it advances its in-licensed CD40L antibody toward a mid-2027 Phase 2 start.
SEC filing
Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
SEC filing (9)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)